[1]
Chrousos, G.P.; Kino, T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann. N. Y. Acad. Sci., 2009, 1179(1), 153-166.
[http://dx.doi.org/10.1111/j.1749-6632.2009.04988.x] [PMID: 19906238]
[http://dx.doi.org/10.1111/j.1749-6632.2009.04988.x] [PMID: 19906238]
[2]
Cohen, S.; Janicki-Deverts, D.; Miller, G.E. Psychological stress and disease. JAMA, 2007, 298(14), 1685-1687.
[http://dx.doi.org/10.1001/jama.298.14.1685] [PMID: 17925521]
[http://dx.doi.org/10.1001/jama.298.14.1685] [PMID: 17925521]
[3]
Agorastos, A.; Chrousos, G.P. The neuroendocrinology of stress: the stress-related continuum of chronic disease development. Mol. Psychiatry, 2022, 27(1), 502-513.
[http://dx.doi.org/10.1038/s41380-021-01224-9] [PMID: 34290370]
[http://dx.doi.org/10.1038/s41380-021-01224-9] [PMID: 34290370]
[4]
Su, W.J.; Hu, T.; Jiang, C.L. Cool the inflamed brain: A novel anti-inflammatory strategy for the treatment of major depressive disorder. Curr. Neuropharmacol., 2024, 22(5), 810-842.
[PMID: 37559243]
[PMID: 37559243]
[5]
Menke, A. The HPA axis as target for depression. Curr. Neuropharmacol., 2024, 22(5), 904-915.
[http://dx.doi.org/10.2174/1570159X21666230811141557] [PMID: 37581323]
[http://dx.doi.org/10.2174/1570159X21666230811141557] [PMID: 37581323]
[6]
Ell, M.A.; Schiele, M.A.; Iovino, N.; Domschke, K. Epigenetics of fear, anxiety and stress - focus on histone modifications. Curr Neuropharmacol., 2024, 22(5), 843-865.
[http://dx.doi.org/10.2174/1570159X21666230322154158] [PMID: 36946487]
[http://dx.doi.org/10.2174/1570159X21666230322154158] [PMID: 36946487]
[7]
Kyriatzis, G.; Khrestchatisky, M.; Ferhat, L.; Chatzaki, E.A. Neurotensin and neurotensin receptors in stress-related disorders: Pathophysiology & novel drug targets. Curr. Neuropharmacol., 2024, 22(5), 916-934.
[PMID: 37534788]
[PMID: 37534788]
[8]
Papageorgiou, M.P.; Theodoridou, D.; Nussbaumer, M.; Syrrou, M.; Filiou, M.D. Deciphering the metabolome under stress: Insights from rodent models. Curr. Neuropharmacol., 2024, 22(5), 884-903.
[http://dx.doi.org/10.2174/1570159X21666230713094843] [PMID: 37448366]
[http://dx.doi.org/10.2174/1570159X21666230713094843] [PMID: 37448366]
[9]
MacKay, M.; Yang, B.H.; Dursun, S.M.; Baker, G.B. The gut-brain axis and the microbiome in anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder. Curr. Neuropharmacol., 2024, 22(5), 866-883.
[http://dx.doi.org/10.2174/1570159X21666230222092029] [PMID: 36815632]
[http://dx.doi.org/10.2174/1570159X21666230222092029] [PMID: 36815632]
[10]
Lochner, C.; Naudé, P.J.W.; Stein, D.J. Use of post-mortem brain tissue in investigations of obsessive- compulsive disorder: A systematic review. Curr. Neuropharmacol., 2024, 22(5), 963-975.
[PMID: 37644747]
[PMID: 37644747]
[11]
Paltoglou, G.; Stefanaki, C.; Chrousos, G.P. Functional MRI techniques suggesting that the stress system interacts with three large scale core brain networks to help coordinate the adaptive response: A systematic review. Curr. Neuropharmacol., 2024, 22(5), 976-989.
[PMID: 37533249]
[PMID: 37533249]
[12]
Cardoner, N.; Andero, R.; Cano, M.; Marin-Blasco, I.; Porta-Casteras, D.; Serra-Blasco, M.; Via, E.; Vicent-Gil, M.; Portella, M. Impact of stress on brain morphology: Insights into structural biomarkers of stress-related disorders. Curr. Neuropharmacol., 2024, 22(5), 935-962.
[http://dx.doi.org/10.2174/1570159X21666230703091435] [PMID: 37403395]
[http://dx.doi.org/10.2174/1570159X21666230703091435] [PMID: 37403395]
19
2